구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Aromatase Inhibitor (AI) |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted and downregulated IGFBP3, thereby restricting the PI3K-AKT signaling |
MoA Biomarker | biomarkers, enhanced trial matching, and scalable cohort identification |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | hepatotoxicity, mutagenicity, carcinogenicity, and cytotoxicity alerts |
Clinical Safety signal | hepatotoxicity, mutagenicity, carcinogenicity, and cytotoxicity alerts |
Clinical Selected reported efficacy | ORR 27% |
Clinical Reported ORR | 27.0% |
Clinical Result source | ClinicalTrials.gov NCT01446159 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01446159 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Aromatase Inhibitor (AI) |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted and downregulated IGFBP3, thereby restricting the PI3K-AKT signaling |
MoA Biomarker | biomarkers, enhanced trial matching, and scalable cohort identification |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | hepatotoxicity, mutagenicity, carcinogenicity, and cytotoxicity alerts |
Clinical Safety signal | hepatotoxicity, mutagenicity, carcinogenicity, and cytotoxicity alerts |
Clinical Selected reported efficacy | ORR 27% |
Clinical Reported ORR | 27.0% |
Clinical Result source | ClinicalTrials.gov NCT01446159 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT01446159 |
추천 비교
추천 비교